CATALOGO DEI PRODOTTI DELLA RICERCA

CORBO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.408
EU - Europa 4.157
AS - Asia 3.501
SA - Sud America 539
AF - Africa 70
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.713
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.325
SG - Singapore 1.313
CN - Cina 1.246
GB - Regno Unito 1.187
IT - Italia 870
HK - Hong Kong 508
BR - Brasile 476
DE - Germania 362
RU - Federazione Russa 329
IE - Irlanda 296
SE - Svezia 280
FR - Francia 267
FI - Finlandia 193
NL - Olanda 113
KR - Corea 99
VN - Vietnam 96
AT - Austria 61
UA - Ucraina 55
CA - Canada 40
IN - India 35
JP - Giappone 32
AU - Australia 31
ES - Italia 31
ID - Indonesia 28
BE - Belgio 27
TG - Togo 24
MX - Messico 19
BD - Bangladesh 18
TR - Turchia 18
AR - Argentina 17
PL - Polonia 15
CZ - Repubblica Ceca 14
IQ - Iraq 14
IR - Iran 14
MA - Marocco 14
ZA - Sudafrica 14
CO - Colombia 13
UZ - Uzbekistan 11
CH - Svizzera 9
EC - Ecuador 9
SA - Arabia Saudita 8
VE - Venezuela 8
PK - Pakistan 7
PY - Paraguay 7
JO - Giordania 6
LT - Lituania 6
AZ - Azerbaigian 5
CR - Costa Rica 5
IL - Israele 5
KG - Kirghizistan 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
TN - Tunisia 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
BG - Bulgaria 4
JM - Giamaica 4
NP - Nepal 4
PA - Panama 4
RS - Serbia 4
CL - Cile 3
DK - Danimarca 3
EG - Egitto 3
HN - Honduras 3
KE - Kenya 3
LV - Lettonia 3
NI - Nicaragua 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DZ - Algeria 2
EE - Estonia 2
HU - Ungheria 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NO - Norvegia 2
OM - Oman 2
RO - Romania 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
CU - Cuba 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
MG - Madagascar 1
Totale 12.707
Salva come PNG Salva come JPEG
Città #
Southend 1.100
Chandler 706
Singapore 601
Dallas 597
Hong Kong 494
Verona 379
Dublin 281
Beijing 263
Ashburn 237
Jacksonville 235
Ann Arbor 220
Woodbridge 206
New York 133
Munich 121
Jinan 107
Lawrence 97
Princeton 97
The Dalles 94
Wilmington 91
Los Angeles 85
Redmond 83
Houston 74
Shenyang 69
Nanjing 66
Helsinki 56
Redondo Beach 56
Turku 50
Hebei 49
São Paulo 46
Columbus 43
Sindelfingen 41
Zhengzhou 40
Haikou 38
Buffalo 37
Tianjin 36
Vienna 36
Changsha 35
Ningbo 34
Santa Clara 34
Dearborn 33
Milan 32
Nuremberg 31
Hangzhou 29
Dong Ket 28
Seattle 28
Brussels 27
Bologna 24
Jakarta 24
Lomé 24
Taiyuan 24
Tokyo 24
Amsterdam 23
Council Bluffs 23
Guangzhou 22
Redwood City 22
San Francisco 22
Lappeenranta 21
Madrid 20
Brooklyn 19
Frankfurt am Main 19
Taizhou 19
Boardman 18
London 18
Jiaxing 17
Nanchang 17
Chicago 16
Norwalk 16
Rome 16
Brescia 15
Hanoi 15
Moscow 15
Seoul 15
Washington 15
Ho Chi Minh City 14
Kent 14
Rio de Janeiro 13
Warsaw 13
Cagliari 12
Lanzhou 11
Sydney 11
Toronto 11
Brasília 10
Brno 10
Curitiba 10
Fuzhou 10
Mexico City 10
Newcastle 10
Stockholm 10
Tashkent 10
Dongguan 9
Falls Church 9
Shanghai 9
St Louis 9
Chions 8
Lancaster 8
Phoenix 8
Belo Horizonte 7
Boston 7
Fairfield 7
Manchester 7
Totale 8.065
Salva come PNG Salva come JPEG
Nome #
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 218
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 206
Whole-genome landscape of pancreatic neuroendocrine tumours 206
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 196
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. 195
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 174
Genomic analyses identify molecular subtypes of pancreatic cancer 168
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 159
RON is not a prognostic marker for resectable pancreatic cancer 154
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 154
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 151
Reporting tumor molecular heterogeneity in histopathological diagnosis 146
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer 146
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 143
PD-1, PD-L1 and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications 140
Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation 138
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 135
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases 134
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 131
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 130
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 127
Molecular biology of neuroendocrine tumors 127
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer 127
Lost in translation: returning germline genetic results in genome-scale cancer research 125
Mutational analysis of cancer candidate genes in different pancreatic cancer types 124
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 124
Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data 124
Complete neural stem cell (nsc) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism 120
Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium 118
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 118
Hypermutation In Pancreatic Cancer 117
Profiling mTOR pathway in neuroendocrine tumors. 117
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 117
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract. 114
Pancreatic cancer genomics 114
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation 114
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 114
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 113
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 112
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer 112
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 111
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. 110
Fhit down-regulation is an early event in pancreatic carcinogenesis 110
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 110
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 110
Sex differences in oncogenic mutational processes 110
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 109
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries 108
Whole genomes redefine the mutational landscape of pancreatic cancer 107
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 107
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling 105
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 105
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 105
Molecular alterations in basal cell carcinoma subtypes 105
Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma 104
Comparative Lesions Analysis Through a Targeted Sequencing Approach 104
Mutational profile of GNAQQ209 in human tumors 103
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 103
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer 103
Exosomal miRNA signatures of pancreatic lesions 101
Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells 101
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC 99
Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas 99
Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study 99
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice 99
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer 98
Generation of Pancreatic Organoid-Derived Isografts 98
Combinatorial Effect of Magnetic Field and Radiotherapy in Pancreatic Ductal Adenocarcinoma Organoids 98
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 97
Profiling mTOR pathway in neuroendocrine tumors 97
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 96
Divergent mutational processes distinguish hypoxic and normoxic tumours 93
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan 93
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients 93
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 90
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing 89
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 89
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 88
Muscle derangement and alteration of the nutritional machinery in NSCLC 87
Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization 85
The RAS and YAP1 dance, who is leading? 84
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 84
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance 84
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 83
Organoid models of human and mouse ductal pancreatic cancer. 83
Loss of FGFR4 promotes the malignant phenotype of PDAC 82
Preclinical Modelling of PDA: Is Organoid the New Black? 82
MEN1 Gene Mutation and Reduced Expression Are Associated with Poor Prognosis in Pulmonary Carcinoids 81
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 81
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer 79
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer 78
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer 77
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer 75
Author Correction: The landscape of viral associations in human cancers 75
Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines 75
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis 74
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer 73
Current role of non-coding RNAs in the clinical setting 73
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 73
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 72
Totale 11.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.133
article - articoli 47.410
book - libri 0
conference - conferenze 1.904
curatela - curatele 0
other - altro 1.701
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.118
Totale 104.266
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021587 0 0 0 135 107 84 23 23 28 25 79 83
2021/2022979 95 311 33 50 39 37 29 58 35 16 76 200
2022/20231.889 113 222 150 328 160 453 23 115 230 19 41 35
2023/20241.225 43 76 78 106 139 211 61 144 29 85 186 67
2024/20253.647 179 161 177 529 201 179 245 216 524 251 373 612
2025/20261.954 691 491 705 67 0 0 0 0 0 0 0 0
Totale 13.030